Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Application Status | |
|---|---|---|---|---|---|
11. |
ECCT/20/07/02 | RV 460 HIV Vaccine Trial A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenicity of Priming with Env-C Plasmid DNA Vaccine Alone, with Different Adjuvants, or with an Adjuvanted HIV Env gp145 C.6980 Protein Vaccine and Boosting with the Adjuvanted HIV Env gp145 C.6980 Protein Vaccine with or without the Env-C Plasmid DNA Vaccine in Healthy HIV Uninfected Adults in Kenya |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI/US MRDA-A/K, KERICHO |
View |
|
12. |
ECCT/20/08/01 | CorNeat EverPatch The CorNeat EverPatch – A First-In-Human Clinical Study for Demonstrating the Safety of a Synthetic Tissue Substitute for Concealment of Artificial Implants and Glaucoma Tube Shunts |
Principal Investigator(s) 1. Lily Adhiambo Nyamai Site(s) in Kenya 1. Lions SightFirst Hospital (Nairobi City county) 2. Kenyatta National Hospital (Nairobi City county) 3. Kwale Eye Centre (Kwale county) |
View |
|
13. |
ECCT/20/06/04 | ANTICOV (01 COV) An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild /moderate cases of COVID-19 |
Principal Investigator(s) 1. Bernhards Ragama Ogutu Site(s) in Kenya 1. Mbagathi Infectious Disease Hospital (Nairobi City county) 2. Kenyatta University Teaching, Referral and Research Hospital (Nairobi City county) |
View |
|
14. |
ECCT/20/07/01 | Convalescent plasma trial A randomized control trial comparing convalescent plasma therapy plus standard treatment versus standard treatment alone in patients with severe COVID-19 pneumonia at a tertiary hospital |
Principal Investigator(s) 1. Dr Isaac Adembesa Kadambi Site(s) in Kenya Kenyatta University Teaching Referral and Research Hospital |
View |
|
15. |
ECCT/20/06/03 | CVIA078 A Phase 2b randomized, open-label, controlled, single center study in Plasmodium falciparum-infected and uninfected adults age 18-55 years old in Kenya to evaluate the efficacy of the delayed, fractional dose RTS,S/AS01E malaria vaccine in subjects treated with artemisinin combination therapy plus primaquine |
Principal Investigator(s) 1. Nathanial Kelsey Copeland Site(s) in Kenya Kombewa Clinical Research Centre |
View |